Media Advisories

Updates for media on the latest products, offerings and developments across our business.

View all
Filter Results
Filter Results
General Financials Partnerships Ad hoc Governance Acquisitions New Products New Technologies Media Advisory Sustainability
Corporate Specialized Modalities Integrated Biologics Capsules & Health Ingredients Advanced Synthesis Bioconjugates Bioscience Cell & Gene Drug Product Services Expression Technologies Mammalian Microbial Personalized Medicine Small Molecules mRNA
2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
English Deutsch French
   Loading...
Showing 1‐20 of 500
14 Oct 2026
Lonza Upgrades Organic Growth Model and Mid-term Financial Ambitions at Capital Markets Day; Q3 2026 In Line with Expectations
With the transformation into a focused, pure-play CDMO complete, and operational and financial performance strengthened, Lonza upgrades its Organic Growth Model and resulting mid-term financial ambitions.
12 Oct 2026
Lonza Expands Dual-Payload ADC Technology Offering Through Exclusive Access to Qurient’s CDK7 Inhibitors
The dual-payload platform agreement adds CDK7 inhibitor technology to Lonza’s technology toolbox for dual-payload ADCs, which can be combined with any other counterpart payloads...
30 Sep 2026
Lonza Nominates Pearl Huang as Independent Board Member
Pearl Huang brings extensive leadership experience in the global pharmaceutical and biotechnology industries and deep scientific expertise. Subject to her election at the Lonza...
10 Sep 2026
Lonza Further Strengthens US Manufacturing Presence with Addition of a Commercial Spray-Drying Facility in Bend, Oregon
Lonza will build a new large-scale, commercial PSD-4 spray-drying facility in Bend, Oregon (US) to support a rapidly expanding market segment The investment will reinforce the...
26 Aug 2026
Lonza Appoints Samanta Cimitan as Chief Commercial Officer
Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and Member of the Extended Executive Committee by 1 January 2027. Samanta brings extensive...
22 Jul 2026
Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook
In H1 2026, Lonza1 delivered sales of CHF 3.4 billion with +16.0% CER2 sales growth The CORE EBITDA margin significantly expanded by +4.4ppts versus H1 2025, reaching 34.8% with a...
22 Jul 2026
Lonza erzielte im ersten Halbjahr 2026 starke Ergebnisse über alle Geschäftsplattformen hinweg und erhöht den Margenausblick für das Gesamtjahr 2026
Im ersten Halbjahr 2026 erzielte Lonza1 einen Umsatz von CHF 3.4 Milliarden bei einem Umsatzwachstum in kWk2 von +16.0% Die Kern-EBITDA-Marge stieg gegenüber dem ersten Halbjahr...
01 Jul 2026
Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company
Further expansion of the existing strategic partnership reflects continued high demand for Lonza’s high-quality global biologics outsourcing development and manufacturing...
30 Jun 2026
Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing
Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market Investment supports Lonza’s position in the...
23 Jun 2026
Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations
Lonza reports restated Half-Year 2025 financials, reflecting Capsules & Health Ingredients (CHI) as discontinued operations, aligned with Full-Year 2025 reporting Restatement...
09 Jun 2026
Lonza Appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026 Hans combines deep...
08 May 2026
Lonza Announces Results of the 2026 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Jean-Marc Huët was re-elected as Chair of the Board of Directors Claudia Süssmuth-Dyckerhoff, Sami Atiya and Stephen Fry were elected as members of the Board of...
08 May 2026
Lonza gibt Ergebnisse der Generalversammlung 2026 bekannt – Alle Anträge des Verwaltungsrates wurden genehmigt
Jean-Marc Huët wurde als Präsident des Verwaltungsrates wiedergewählt Claudia Süssmuth-Dyckerhoff, Sami Atiya und Stephen Fry wurden als Mitglieder des Verwaltungsrates...
08 May 2026
Lonza¹ Delivers Strong Performance in Q1 2026 in Line with Expectations and Confirms Full-Year Outlook 2026
Strong CDMO1 performance in Q1 2026, in line with expected H1-weighted growth and Full-Year 2026 margin trajectory – despite a changing geopolitical landscape, evolving trade...
01 Apr 2026
Lonza Publishes 2026 Annual General Meeting Invitation and 2025 Annual and Sustainability Reports
Annual General Meeting will take place on 8 May 2026 at the Congress Center in Basel, Switzerland Jean-Marc Huët proposed for re-election as Chair of the Board of...
31 Mar 2026
Lonza Nominates Stephen Fry as Independent Board Member
Stephen Fry is nominated to the Lonza Board for his extensive track record in the pharma industry and deep experience in performance culture and organizational...
09 Mar 2026
Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™
Extended agreement will expand manufacturing capacity at Lonza Houston (US) to support growing demand for Genetix’s ZYNTEGLO™ (betibeglogene autotemcel), the only FDA-approved gene...
06 Mar 2026
Lonza Completes its Transformation to a Pure-Play CDMO with Agreement to Divest Capsules & Health Ingredients
Lonza signs agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds, for an enterprise value of CHF 2.3 billion (USD 3 billion) at closing. The...
13 Feb 2026
Changes to the Composition of the Lonza Board
Sami Atiya is nominated to the Lonza Board for his deep experience in healthcare, robotics, automation and AI acquired from senior roles at ABB, Siemens and other leading...
28 Jan 2026
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration
In 2025, Lonza1 delivered sales of CHF 6.5 billion with +21.7% CER2 growth, and a CORE EBITDA of CHF 2.1 billion at a margin of 31.6% (+1.4ppts versus prior year), outperforming...